Supernus Pharmaceuticals (SUPN) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Company overview and leadership

• Focuses on CNS therapeutics, including ADHD, postpartum depression, and Parkinson's disease, with both R&D and commercial products.

• Updated 2023 guidance projects $860M–$890M in revenue and $150M–$180M in adjusted EBITDA.

• Recent acquisition of Sage brought Zurzuvae, the only approved postpartum depression drug, marketed with Biogen.

• Announced intent to merge with Indivior, aiming to close in Q4, to accelerate growth and diversification.

• Leadership emphasizes transparent, realistic guidance and a collaborative, vision-driven culture.

Product portfolio and performance

• Qelbree, a novel non-stimulant for ADHD, shows strong growth: 25% in adult and 14% in pediatric prescriptions in Q2.

• Qelbree offers rapid onset and is differentiated by efficacy in both ADHD and comorbid depression/anxiety.

• ONAPGO for Parkinson's overcame supply constraints, with 2023 guidance raised to $55M–$70M and supply secured through 2027.

• ONAPGO peak sales estimated at $200M–$300M, with potential upside if use expands to less severe patients.

• Zurzuvae launch for postpartum depression exceeds expectations, supported by DTC campaigns and provider education.

Strategic initiatives and future outlook

• Merger with Indivior expected to create a diversified portfolio and enhance cash flow, enabling further R&D and M&A.

• Post-merger priorities include resourcing key brands, expanding R&D, and exploring shareholder return strategies.

• Pipeline includes SPN-820 for depression, advancing an intermittent dosing strategy based on mTORC1 modulation.

• SPN-817 for epilepsy and multiple early-stage discovery programs are in development, with more details to be unveiled.

• Leadership remains focused on innovation, growth, and maximizing shareholder value through strategic investments.